CNBC’s Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. Make some room on ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

To treat depression, the tech magnate has said he'd rather use ketamine, a dissociative anesthetic, than traditional antidepressants.

Mind-opening psychedelic drugs can provide a needed boost to people dealing with cancer or struggling with alcoholism, ...

After six weeks, both the treatment group and the placebo group experienced an average 12.5-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS). The drug also fell short in i ...

Studies show psilocybin from mushrooms could revolutionize depression treatment offering hope to millions who don't respond to traditional medications.

Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...

Thomas Trutschel / Photothek via Getty Images Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged. The biopharmaceutical firm's navacaprant ...

s shares plummeted the most on record after the company’s experimental drug for the treatment of ... significant improvement in a measurement of depression symptoms, the company said Thursday.